Skip to main content
SpringerLink
Log in

Intralesional and Perilesional Treatment of Skin Cancers

  • Chapter
  • First Online:
Skin Cancer Management

Abstract

In the following chapter, various intralesional and perilesional agents that have been used in the treatment of skin cancers will be presented by practitioners familiar with their use. The four medications reviewed have been in widespread use for many years in the treatment of cutaneous neoplasms and extracutaneous neoplastic and inflammatory conditions. Therefore, the efficacy, toxicity, delivery, indications, and costs for these agents are well established, and they are widely available. However, the most common routes of administration for such medications are oral, intravenous, and topical. An intralesional and perilesional approach to therapy is less often utilized, leading to less familiarity in clinical practice. It is our hope that a detailed review of these agents delivered in such a manner, along with a variety of clinical examples, will facilitate their use in practice and increase the variety of treatment options available to patients with cutaneous tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Olsen EA. The pharmacology of methotrexate. J Am Acad Dermatol. 1991;25:306–318.

    Article  CAS  PubMed  Google Scholar 

  2. Glantz MJ, Jaeckle KA, Chamberlain MC, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res. 1999;5:3394–3402.

    CAS  PubMed  Google Scholar 

  3. Nystrom ML, Steele JP, Shamash J, et al. Low-dose continuous chemotherapy for metastatic melanoma: a phase II trial. Melanoma Res. 2003;13:197–199.

    Article  CAS  PubMed  Google Scholar 

  4. Colevas AD. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2006;24:2644–2652.

    Article  CAS  PubMed  Google Scholar 

  5. Sheen YS, Sheen MC, Sheu HM, et al. Squamous cell carcinoma of the big toe successfully treated by intra-arterial infusion with methotrexate. Dermatol Surg. 2003;29:982–983.

    Article  PubMed  Google Scholar 

  6. Coker DD, Elias EG, Viravathana T, et al. Chemotherapy for metastatic basal cell carcinoma. Arch Dermatol. 1983;119:44–50.

    Article  CAS  PubMed  Google Scholar 

  7. Bason MM, Grant-Kels JM, Govil M. Metastatic basal cell carcinoma: response to chemotherapy. J Am Acad Dermatol. 1990;22:905–908.

    Article  CAS  PubMed  Google Scholar 

  8. Annest NM, Van Beek MJ, Arpey CJ, et al. Intralesional methotrexate injection for keratoacanthoma tumors: a retrospective study and review of the literature. J Am Acad Dermatol. 2007;56:989–993.

    Article  PubMed  Google Scholar 

  9. Beham A, Regauer S, Soyer HP, et al. Keratoacanthoma: a clinically distinct variant of well differentiated squamous cell carcinoma. Adv Anat Pathol. 1998;5(5):269–280.

    Article  CAS  PubMed  Google Scholar 

  10. Manstein CH, Frauenhoffer CJ, Besden JE. Keratoacanthoma: is it a real entity? Ann Plast Surg. 1998;40(5):469–472.

    Article  CAS  PubMed  Google Scholar 

  11. Karaa A, Khachemoune A. Keratoacanthoma: a tumor in search of a classification. Int J Dermatol. 2007;46:671–678.

    Article  PubMed  Google Scholar 

  12. Schwartz RA. Keratoacanthoma: a clinico-pathologic enigma. Dermatol Surg. 2004;30:326–333.

    Article  PubMed  Google Scholar 

  13. LeBoit PE. Can we understand keratoacanthoma? Am J Dermatopathol. 2002;24:166–168.

    Article  PubMed  Google Scholar 

  14. Hodak E, Jones RE, Ackerman AB. Solitary keratoacanthoma is a squamous cell carcinoma: three examples with metastases. Am J Dermatopathol. 1993;15:332–342.

    Article  CAS  PubMed  Google Scholar 

  15. Sanders S, Busam KJ, Halpern AC, et al. Intralesional corticosteroid treatment of multiple eruptive keratoacanthomas: case report and review of a controversial therapy. Dermatol Surg. 2002;28:954–958.

    Google Scholar 

  16. Eubanks SW, Gentry RH, Patterson JW, et al. Treatment of multiple keratoacanthomas with intralesional fluorouracil. J Am Acad Dermatol. 1982;7:126–129.

    Article  CAS  PubMed  Google Scholar 

  17. Leonard AL, Hanke CW. Treatment of giant keratoacanthoma with intralesional 5-fluorouracil. J Drugs Dermatol. 2006;5:454–456.

    PubMed  Google Scholar 

  18. Morse LG, Kendrick C, Hooper D, et al. Treatment of squamous cell carcinoma with intralesional 5-Fluorouracil. Dermatol Surg. 2003;29:1150–1153.

    Article  PubMed  Google Scholar 

  19. Sayama S, Tagami H. Treatment of keratoacanthoma with intralesional bleomycin. Br J Dermatol. 1983;109:449–452.

    Article  CAS  PubMed  Google Scholar 

  20. de la Torre C, Losada A, Cruces MJ. Keratoacanthoma centrifugum marginatum: treatment with intralesional bleomycin. J Am Acad Dermatol. 1997;37:1010–1011.

    Article  PubMed  Google Scholar 

  21. Andreassi A, Pianigiani E, Taddeucci P, et al. Guess what! Keratoacanthoma treated with intralesional bleomycin. Eur J Dermatol. 1999;9:403–405.

    CAS  PubMed  Google Scholar 

  22. Klein E, Milgram H, Traenkle HL. Tumors of the skin. II: Keratoacanthoma; local effect of 5-fluorouracil (5-FU). Skin. 1962;1:153–156.

    CAS  PubMed  Google Scholar 

  23. Bergin DJ, Lapins NA, Deffer TA. Intralesional 5-fluorouracil for keratoacanthoma of the eyelid. Ophthal Plast Reconstr Surg. 1986;2(4):201–204.

    Article  CAS  PubMed  Google Scholar 

  24. Parker CM, Hanke CW. Large keratoacanthomas in difficult locations treated with intralesional 5-fluorouracil. J Am Acad Dermatol. 1986;14:770–777.

    Article  CAS  PubMed  Google Scholar 

  25. Thiele JJ, Ziemer M, Fuchs S, et al. Combined 5-fluorouracil and Er:YAG laser treatment in a case of recurrent giant keratoacanthoma of the lower leg. Dermatol Surg. 2004;30:1556–1560.

    Article  PubMed  Google Scholar 

  26. Feldman RJ, Maize JC. Multiple keratoacanthomas in a young woman: report of a case emphasizing medical management and a review of the spectrum of multiple keratoacanthomas. Int J Dermatol. 2007;46:77–79.

    Google Scholar 

  27. Mangas C, Bielsa I, Ribera M, et al. A case of multiple keratoacanthoma centrifugum marginatum. Dermatol Surg. 2004;30:803–806.

    Article  PubMed  Google Scholar 

  28. Vergara A, Isaría MJ, Domínguez JD, et al. Multiple and relapsing keratoacanthomas developing at the edge of skin grafts site after surgery and after radiotherapy. Dermatol Surg. 2007;33:994–996.

    Article  CAS  PubMed  Google Scholar 

  29. Street ML, White Jr JW, Gibson LE. Multiple keratoacanthomas treated with oral retinoids. J Am Acad Dermatol. 1990;23:862–866.

    Article  CAS  PubMed  Google Scholar 

  30. Benoldi D, Alinovi A. Multiple persistent keratoacanthomas: treatment with oral etretinate. J Am Acad Dermatol. 1984;10:1035–1038.

    Article  CAS  PubMed  Google Scholar 

  31. Benest L, Kaplan RP, Salit R, et al. Keratoacanthoma centrifugum marginatum of the lower extremity treated with Mohs micrographic surgery. J Am Acad Dermatol. 1994;31:501–502.

    Article  CAS  PubMed  Google Scholar 

  32. Larson PO. Keratoacanthomas treated with Mohs micrographic surgery (chemosurgery): a review of forty-three cases. J Am Acad Dermatol. 1987;16:1040–1044.

    Article  CAS  PubMed  Google Scholar 

  33. Goldschmidt H, Sherwin WK. Radiation therapy of giant aggressive keratoacanthomas. Arch Dermatol. 1993;129(9):1162–1165.

    Article  CAS  PubMed  Google Scholar 

  34. Caccialanza M, Sopelana N. Radiation therapy of keratoacanthomas: results in 55 patients. Int J Radiat Oncol Biol Phys. 1989;16(2):475–477.

    Article  CAS  PubMed  Google Scholar 

  35. Reymann F. Treatment of Keratoacanthomas with curettage. Dermatologica. 1997;155(2):90–96.

    Article  Google Scholar 

  36. Nedwich JA. Evaluation of curettage and electrodesiccation in treatment of keratoacanthoma. Australas J Dermatol. 1991;32(3):137–141.

    Article  CAS  PubMed  Google Scholar 

  37. Sheridan AT, Dawber RP. Curettage, electrosurgery and skin cancer. Australas J Dermatol. 2000;41(1):19–30.

    Article  CAS  PubMed  Google Scholar 

  38. Oh CK, Son HS, Lee JB, et al. Intralesional interferon alfa-2b treatment of keratoacanthomas. J Am Acad Dermatol. 2004;51(6):1040.

    Google Scholar 

  39. Dendorfer M, Oppel T, Wollenberg A, et al. Topical treatment with imiquimod may induce regression of facial keratoacanthoma. Eur J Dermatol. 2003;13 (1):80–82.

    PubMed  Google Scholar 

  40. Goebeler M, Lurz C, Kolve-Goebeler ME, et al. Pancytopenia after treatment of keratoacanthoma by single lesional methotrexate infiltration. Arch Dermatol. 2001;137(8):1104–1105.

    CAS  PubMed  Google Scholar 

  41. Cohen PR, Schulze KE, Nelson BR. Pancytopenia after a single intradermal infiltration of methotrexate. J Drugs Dermatol. 2005;4(5):648–651.

    PubMed  Google Scholar 

  42. Melton JL, Nelson BR, Stough DB, et al. Treatment of keratoacanthomas with intralesional methotrexate. J Am Acad Dermatol. 1991;25:1017–1023.

    Article  CAS  PubMed  Google Scholar 

  43. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanomas. Clin Oncol. 2005;23:2346–2357.

    Article  CAS  Google Scholar 

  44. Greenway HT, Cornell RC, Tanner DJ, et al. Treatment of basal cell carcinomas with intralesional interferon. J Am Acad Dermatol. 1986;15:437–443.

    Article  CAS  PubMed  Google Scholar 

  45. Mozzanica N, Cattaneo A, Boneschi L, et al. Immunohistological evaluation of basal cell carcinoma immunoinfiltrate during intralesional treatment with alpha 2 interferon. Arch Dermatol Res. 1990;282(5):311–317.

    Article  CAS  PubMed  Google Scholar 

  46. Tong Y, Tucker SB. Normal human skin lymphocytic and Langerhans’ cell responses to intradermal interferon α2b injections. Am J Med Sci. 1993;306:23–27.

    Article  CAS  PubMed  Google Scholar 

  47. Tucker SB, Polasek JW, Perri AJ, et al. Long term follow-up of basal cell carcinomas treated with perilesional interferon alfa 2b as monotherapy. J Am Acad Dermatol. 2006;54:1033–1038.

    Article  PubMed  Google Scholar 

  48. Tucker SB. Interferon-alpha treatment of basal cell and squamous cell skin tumors. Cancer Bull. 1993;45:270–274.

    Google Scholar 

  49. Edwards L, Berman B, Rapini RP, et al. Treatment of cutaneous squamous cell carcinomas by intralesional interferon alfa-2b therapy. Arch Dermatol. 1992;128:1486–1489.

    Article  CAS  PubMed  Google Scholar 

  50. Carucci JA. Intralesional interferon alfa for treatment of recurrent lentigo maligna of the eyelid in a patient with primary acquired melanosis. Arch Dermatol. 2000;136:1415.

    Article  CAS  PubMed  Google Scholar 

  51. Cornell RC, Greenway HT, Tucker SB, et al. Intralesional interferon therapy of basal cell carcinoma. J Am Acad Dermatol. 1990;23:694–700.

    Article  CAS  PubMed  Google Scholar 

  52. Miller BH, Shavin JS, Cognetta A, et al. Nonsurgical treatment of basal cell carcinomas with intralesional 5-fluoruracil injectable gel. J Am Acad Dermatol. 1997;36:72–77.

    Article  CAS  PubMed  Google Scholar 

  53. Odom RB, Goette DK. Treatment of keratoacanthomas with intralesional fluorouracil. Arch Dermatol. 1978;114:1779–1983.

    Article  CAS  PubMed  Google Scholar 

  54. Goette DK, Odom RB. Successful treatment of keratoacanthoma with intralesional fluorouracil. J Am Acad Dermatol. 1980;2:212–216.

    Article  CAS  PubMed  Google Scholar 

  55. Kurtis B, Rosen T. Treatment of cutaneous neoplasms by intralesional injections of 5-fluorouracil (5-FU). J Dermatol Surg Oncol. 1980;6:122–127.

    CAS  PubMed  Google Scholar 

  56. Kraus S, Miller BH, Swinehart JM, et al. Intratumoral chemotherapy with fluorouracil/epinephrine injectable gel: a nonsurgical treatment of cutaneous squamous cell carcinoma. J Am Acad Dermatol. 1998;38:438–442.

    Article  CAS  PubMed  Google Scholar 

  57. Avant WH, Huff RC. Intradermal 5-flurouracil in the treatment of basal cell carcinoma of the face. South Med J. 1976;69:561–563.

    CAS  PubMed  Google Scholar 

  58. Hanke CW. Treatment of squamous cell carcinoma with intralesional 5-FU (Comment). Dermatol Surg. 2003;29(11):1153.

    Google Scholar 

  59. Kurtis B, Rosen T. Squamous cell carcinoma arising in a basal cell epithelioma treated with 5-fluorouracil. J Dermatol Surg Oncol. 1979;5:394–396.

    CAS  PubMed  Google Scholar 

  60. Umezawa H, Maeda K, Takeuchi T, et al. New antibiotics, bleomycin A and B. J Antibiot. 1966;19:200–209.

    CAS  PubMed  Google Scholar 

  61. Burger RM, Peisach J, Horwitz SB. Activated bleomycin: a transient complex of drug, iron and oxygen that degrades DNA. J Biol Chem. 1981;256:1636–1644.

    Google Scholar 

  62. Saitta P, Krishnamurthy K, Brown LH. Bleomycin in dermatology: a review of intralesional applications. Dermatol Surg. 2008;34:1299–1313.

    Google Scholar 

  63. Mizuno S, Ishida A. Selective enhancement of bleomycin cytotoxicity by local anesthetics. Biochem Biophys Res Commun. 1982;105:425–431.

    Article  CAS  PubMed  Google Scholar 

  64. Belehradek M, Domenge C, Luboinski B, et al. Electrochemotherapy, a new antitumor treatment. Cancer. 1993;72:3694–3700.

    Article  CAS  PubMed  Google Scholar 

  65. Glass F, Pepine M, Fenske N, et al. Bleomycin-mediated electrochemotherapy of metastatic melanoma. Arch Dermatol. 1996;132:1353–1357.

    Article  CAS  PubMed  Google Scholar 

  66. Torre C, Losada A, Cruces M. Keratoacanthoma centrifugum marginatum: treatment with intralesional bleomycin. J Am Acad Dermatol. 1997;37:1010–1011.

    Article  PubMed  Google Scholar 

  67. Fantini F, Gualdi G, Cimitan A, et al. Metastatic basal cell carcinoma with squamous differentiation. Arch Dermatol. 2008;144(9):1186–1188.

    Article  PubMed  Google Scholar 

  68. Omidvari S, Nezakatgoo N, Ahmadloo N, et al. Role of intralesional bleomycin in the treatment of complicated hemangiomas; prospective clinical study. Dermatol Surg. 2005;31:499–501.

    Article  CAS  PubMed  Google Scholar 

  69. Bunney M. Intralesional bleomycin sulfate in treatment of recalcitrant warts. Clin Dermatol. 1985;3:189–194.

    Article  CAS  PubMed  Google Scholar 

  70. Miller R. Nail dystrophy following intralesional injections of bleomycin for a periungual wart. Arch Dermatol. 1984;120:963–964.

    Article  CAS  PubMed  Google Scholar 

  71. Polluck B, Sheehan-Dare R. Pulsed dye laser and intralesional bleomycin for treatment of resistant viral hand warts. Lasers Surg Med. 2002;30:135–140.

    Article  Google Scholar 

  72. Susser W, Whitaker-White D, Grant-Kies J. Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol. 1999;40:367–398.

    Article  CAS  PubMed  Google Scholar 

  73. Pienaar C, Graham R, Geldenhuys S, et al. Intralesional bleomycin for the treatment of hemangiomas. Plastic Reconstruct Surg. 2006;117:221–226.

    Article  CAS  Google Scholar 

  74. Smith EA, Harber FE, Leroy EG, et al. Raynaud’s phenomenon of a single digit following local intradermal bleomycin sulfate injection. Arthritis Rheum. 1985;28:459–461.

    Article  CAS  PubMed  Google Scholar 

  75. Heller R, Jaroszeski M, Reintgen D, et al. Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin. Cancer. 1998;83:148–157.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA

    Christopher J. Arpey MD (Professor)

  2. Kaiser Permanente, Mohs Surgical Unit, Department of Dermatology, Lafayette, CO, USA

    Nicole M. Annest MD, MS (Staff Physician)

  3. Department of Dermatology, University of Texas Health Science Center at Houston, Houston, TX, USA

    Stephen B. Tucker MD (Clinical Professor of Dermatology)

  4. Department of Dermatology, University of Texas Medical School, Houston, TX, US

    Ronald P. Rapini MD (Professor and Chair, MD Anderson Cancer Center)

  5. Departments of Dermatology and Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Deborah F. MacFarlane MD, MPH (Professor)

Authors
  1. Christopher J. Arpey MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicole M. Annest MD, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stephen B. Tucker MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ronald P. Rapini MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Deborah F. MacFarlane MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. One Hermann Museum Circle , Houston, 77004, U.S.A.

    Deborah F. MacFarlane

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Arpey, C.J., Annest, N.M., Tucker, S.B., Rapini, R.P., MacFarlane, D.F. (2009). Intralesional and Perilesional Treatment of Skin Cancers. In: MacFarlane, D.F. (eds) Skin Cancer Management. Springer, New York, NY. https://doi.org/10.1007/978-0-387-88495-0_5

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-88495-0_5

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-88494-3

  • Online ISBN: 978-0-387-88495-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation